An observational study in Esophageal Squamous Cell Carcinoma (ESCC), Cervical Squamous Cell Carcinoma and Lung Squamous Cell Carcinoma, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-18.
Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Esophageal Squamous Cell Carcinoma by Cancer Institute and Hospital, Chinese Academy of Medical Sciences — 5 open to participants now, 9 under way, none of them phase 3. Esophageal Squamous Cell Carcinoma · Cancer Institute and Hospital, Chinese Academy of Medical Sciences.
Among the 10 studies in Esophageal Squamous Cell Carcinoma by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, this one is one of 2 that started in 2025, is one of 4 observational ones, and was the 7th registered.
678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.
Browse Esophageal Squamous Cell Carcinoma studies →5 of the 10 studies in Esophageal Squamous Cell Carcinoma by Cancer Institute and Hospital, Chinese Academy of Medical Sciences are open now, in 1 country. Recruiting first, the newest first:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–80
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18+
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–80
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–80
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–85
By country, each count listing its studies:
Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4
First in 2018; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 800 is above the median of 225 across 88 observational studies indexed under Esophageal Squamous Cell Carcinoma.
Median enrollment 121 across the 6 interventional studies, 550 across the 4 observational. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences is the lead sponsor of 396 studies on the registry; 281 are open to participants now.
3 of the studies in Esophageal Squamous Cell Carcinoma by Cancer Institute and Hospital, Chinese Academy of Medical Sciences that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06342167Cancer Institute and Hospital, Chinese Academy of Medical SciencesEfficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma | 2026-12-01 |
| NCT07147361Cancer Institute and Hospital, Chinese Academy of Medical SciencesPredictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma | 2026-12-31 |
| NCT05951127Cancer Institute and Hospital, Chinese Academy of Medical SciencesAdditional Consolidative Esophagectomy for the Patients With Oligometastatic Resectable ESCC | 2027-10-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies in Esophageal Squamous Cell Carcinoma by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This multicenter retrospective-prospective cohort study evaluates predictive biomarker and tissue-pathology features for response to PD-1 inhibitor-based therapy in patients with squamous cell carcinoma (SCC). Model inputs include blood ELISA, tissue multiplex immunofluorescence (mIF), PD-L1 assessment, pretreatment biopsy/H\&E-based pathology features, and baseline clinicopathological variables, assessed individually or in combination.
The retrospective component will analyze clinical data and pretreatment tissue and blood specimens from SCC patients treated with PD-1 inhibitor-based therapy from May 2020 onward across participating centers. These data will be used to develop and refine a predictive model or risk-score framework and to evaluate associations with objective response rate (ORR), pathological response where applicable, duration of response (DoR), progression-free survival (PFS), event-free survival (EFS), and overall survival (OS).
The prospective component begins in September 2025 and will enroll up to 800 participants. Eligible patients may receive PD-1 inhibitor therapy with or without chemotherapy, including disease-specific cohorts receiving neoadjuvant anti-PD-1 therapy plus chemotherapy where applicable.
Baseline clinical data and pretreatment samples will be collected before treatment initiation. Tumor tissue, biopsy or H\&E slides obtained within 6 months where available, and blood samples collected within 28 days where available will be used for biomarker and tissue-pathology analyses.
Patients will be followed at baseline and at weeks 4, 8, and 12 where applicable, with quarterly survival follow-up. Response may be assessed using RECIST 1.1 and/or pathological response criteria, including tumor regression grade where applicable; for neoadjuvant patients, postoperative tumor regression grade and treatment failure before surgery may be incorporated according to a prespecified response-assessment rule.
Within the prospective component, the ESCC-specific cohort includes consecutive treatment-naive patients receiving neoadjuvant anti-PD-1 blockade plus chemotherapy and supports locked-model evaluation using pretreatment endoscopic biopsy H\&E slides.
Background and Rationale Squamous Cell Carcinoma (SCC) is a malignancy arising from squamous epithelium, affecting multiple organs including the skin, oral cavity, esophagus, lungs, and cervix. It is characterized by a high incidence rate and significant mortality.
Lung Squamous Cell Carcinoma (LUSC): In 2022, China accounted for 42.8% of new global lung cancer cases and 40.3% of deaths. LUSC is a major subtype, strongly associated with smoking, and is characterized by rapid cell proliferation and a high potential for invasion and metastasis.
This innovative retrospective-prospective cohort study will integrate real-world clinical data with biological samples to build and validate a predictive model specifically for Chinese patients with SCC, aiming to guide clinical decision-making and optimize resource allocation.
Study Objectives
<!-- -->
Study Design This is a multi-center, cohort study with both retrospective and prospective components.
This phase begins in September 2025 and aims to enroll up to 800 participants to validate the predictive model or risk-score framework developed from the retrospective data. Patients may include those receiving PD-1 inhibitor therapy with or without chemotherapy, including disease-specific cohorts receiving neoadjuvant anti-PD-1 therapy plus chemotherapy where applicable, and will be stratified according to the model's risk score, based on:
Low risk of treatment resistance as indicated by the same scoring system. 5. Study Population
Capacity to provide written informed consent.
1. Presence of other concurrent malignancies. 2. History of prior anti-cancer treatments for the current diagnosis. 6. Study Endpoints
7. Sample Size Calculation The sample size was calculated using a one-sample ROC curve analysis. Based on an expected AUC of 0.85 versus a null hypothesis threshold of AUC > 0.8, with a one-sided alpha of 0.05 and 80% power, the required sample size is 165 participants. Accounting for a 20% potential dropout rate, the study plans to enroll 200 participants for each of the four SCC subtypes, for a total of 800 participants.
8. Study Procedures
9. Sample Collection and Management
Blood Samples: Residual blood samples from routine clinical draws will be collected. Samples will be centrifuged to separate serum, which will then be stored at -80°C for future ELISA analysis.
10. Statistical Analysis Plan
Sensitivity Analyses: Analyses will be conducted to test the robustness of the findings, including using different adjustment sets in multivariable models and analyzing the prospective cohort data exclusively for validation.
11. Ethical Considerations This study will be conducted in full compliance with the principles of the Declaration of Helsinki and Good Clinical Practice (GCP) guidelines. The study protocol will be submitted to and approved by the Institutional Review Board (IRB)/Ethics Committee (EC) at each participating site before patient enrollment. All participants will undergo a thorough informed consent process, conducted by trained research staff in a private setting, and will be required to provide written informed consent before any study-related procedures are performed. Patient confidentiality will be strictly maintained.
This study enrolls patients with confirmed squamous cell carcinoma (SCC), including esophageal, head/neck, cervical, and lung subtypes, regardless of resectability. Participants must be scheduled for neoadjuvant or first-line PD-1 inhibitor therapy and provide pretreatment tumor and blood samples. Key inclusion requires capacity for informed consent; concurrent malignancies or prior anticancer treatments are exclusions. All subjects must provide written informed consent and undergo baseline assessments: clinical data collection, archival/fresh tumor tissue acquisition (within 6 months), and peripheral blood sampling (within 28 days) for biomarker analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with pathologically confirmed esophageal, head and neck, cervical, or lung squamous cell carcinoma who received PD-1 inhibitor-based therapy, with or without chemotherapy, at participating centers from May 2020 onward. Existing baseline clinical data and available pretreatment tumor biopsy tissue, H\&E slides, and blood specimens are retrospectively collected for development and refinement of biomarker- and tissue-based prediction models and for evaluation of associations with treatment response and time-to-event outcomes. Treatment was selected as part of routine clinical care and was not assigned by this observational study.
Adults with pathologically confirmed esophageal, head and neck, cervical, or lung squamous cell carcinoma are prospectively enrolled from September 2025 before planned PD-1 inhibitor-based therapy, with or without chemotherapy. Within this prospective component, the ESCC-specific cohort includes consecutive treatment-naive patients receiving neoadjuvant anti-PD-1 blockade plus chemotherapy at the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. Pretreatment clinical data and available tumor tissue, H\&E slides, and blood samples are collected, and participants are followed for treatment response and survival outcomes. Treatment is selected as part of routine clinical care and is not assigned by this observational study.
Area under ROC curve
The primary outcome is the area under the receiver operating characteristic curve (AUC) of the predictive model or risk-score framework for classifying patient-level treatment response to PD-1 inhibitor-based therapy. Treatment response may be assessed using RECIST 1.1 and/or pathological response criteria, including tumor regression grade where applicable.
Time frame: From enrollment to protocol-defined response assessment, up to 6 months.
Event-free survival
EFS is defined as the time from enrollment to disease progression, recurrence, failure to proceed to surgery where applicable, non-protocol anticancer therapy for suspected progression or non-response, death, or last follow-up.
Time frame: From enrollment to first event or last follow-up, up to 5 years.
Overall survival
Overall survival is defined as the time from enrollment to death from any cause or last follow-up.
Time frame: From enrollment to death or last follow-up, up to 5 years.
Started Sep 2025 (actual). Primary completion is estimated for Dec 2026, 15 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Esophageal Squamous Cell Carcinoma →
Cancer Institute and Hospital, Chinese Academy of Medical Sciences →